WZ4002 | WZ4002 : Covalent, mutant selective inhibitor of EGFR
RATINGS:
Cellular Use: (3 reviews)

In Model Organisms: (3 reviews)
Control Compounds

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
EGFR (Mutant:WT, T790M, L858R, L858R/T790M)
  • KD:14 WT, 2.2 T790M, 1.5 L858R, 0.13 L858R/T790M nM
  • IC50:2 nM EGFR-L858R; 8 nM EGFR-L858R/T790M; 3 nM EGFR (del); 2 nM EGFR (del/T790M)
Covalent Inhibitor
up to 100 nM

Selectivity

In Vitro Selectivity Assessment
Selectivity Assessment Description:
Profiled against a panel of 400 kinases using the Ambit kinome screening platform. wildetype ERBB ...

Potency
Cellular
In Vitro

EGFR (Mutant:WT, T790M, L858R, L858R/T790M)

Mode of Action: Covalent Inhibitor

Structure-Activity-Relationship data available? Yes

In Vivo Validations

Mouse
Dose: 1 mg/Kg IV, 10-25 mg/Kg PO
Route of delivery: Intravenous, Oral
Plasma half life: 2.46 h PO, 1.76 h IV
Systemic clearance: 17.1 mL/min/Kg

Reference: --

Orthogonal Probes def

ROCILETINIB

Chemical Information

Molecular Formula C25H27ClN6O3
SMILEs C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1
InChI InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30)
Molecular weight 494.18 Da
AlogP 0.0
HBond acceptors 9
HBond donors 2
Atoms 62

References

Publications

    Vendors

    Note: This is not an exhaustive list and does not indicate endorsement by the portal.

    Expert Reviews


    (on 2 Mar 2021 )
    Cellular Use Rating
    In Model Organisms
    WZ4002 is a covalent inhibitor of EGFR variants carrying the T790M mutant. The cmpd shows roughly a 10fold selectivity window vs. EGFR wt in cellular studies which also translates into in vivo studies....
    (on 2 Mar 2021 )
    Cellular Use Rating
    In Model Organisms
    This is a covalent inhibitor of various EGFR mutants and is potent in biochemical and cellular assays. Depending on the cell line used, the selectivity for EGFR over other cysteine containing kinases,...
    (on 12 Mar 2021 )
    Cellular Use Rating
    In Model Organisms
    WZ4002 is identified as a covalent inhibitor potent against EGFR mutants including both primary activating mutations (e.g., L858R, ΔE746-A750) and resistant mutation T790M (e.g., L858R/T790M, ΔE746-A750/T790M...
    Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria